Richard O Chen Selected Research

sotigalimab

1/2022	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
1/2021	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard O Chen Research Topics

Disease

4	Neoplasms (Cancer) 12/2022 - 10/2012
2	Adenocarcinoma 01/2022 - 01/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Septic Shock (Toxic Shock Syndrome) 01/2021
1	Sepsis (Septicemia) 01/2021

Drug/Important Bio-Agent (IBA)

3	NivolumabIBA 01/2022 - 01/2021
2	sotigalimabIBA 01/2022 - 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2022
1	AntigensIBA 01/2022
1	IpilimumabIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	130-nm albumin-bound paclitaxelIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Gemcitabine FDA Link 01/2021
1	Long Noncoding RNAIBA 10/2012

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2022 - 01/2021
2	Immunotherapy 01/2022 - 01/2021